Ombretta Repetto1, Lara Mussolin2, Caterina Elia3, Lia Martina4, Maurizio Bianchi5, Salvatore Buffardi6, Alesandra Sala7, Roberta Burnelli8, Maurizio Mascarin9, Valli De Re10
1Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, CRO Aviano National Cancer Institute, Italy,2Clinic of Pediatric Haemato-Oncology, Department of Women's and Children's Health, University of Padua, Padua, Institute of Paediatric Research – Fondazione Città della Speranza, Padua, Italy,3Pediatric Radioterapy Unit, Centro di Riferimento Oncologico, CRO, IRCCS, Aviano, Italy,4Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, CRO Aviano National Cancer Institute, Italy,5Pediatric Onco-Hematology and Stem Cell Transplant Division, City of Health and Science, Regina Margherita Children‘s Hospital, Turin, Italy,6Paediatric Haemato-Oncology department, Santobono-Pausilipon Children‘s Hospital, Napoli, Italy,7Department of Paediatrics, Ospedale San Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy,8Pediatric Oncology University Hospital, Sant‘Anna Hospital, Ferrara, Italy,9Pediatric Radioterapy Unit, Centro di Riferimento Oncologico, CRO, IRCCS, Aviano, Italy,10 Facility of Bio-Proteomics, Immunopathology and Cancer Biomarkers, CRO Aviano National Cancer Institute, Italy
The treatment of paediatric Hodgkin lymphoma (HL) has steadily improved over the years, so that 10- years survival exceed 80%. The -purpose of this study was to identify prognostic markers for relapsed HL that might contribute to optimize therapeutic approaches. We analysed differential protein expression profiles obtained from plasma of children/adolescents with HL (age ranging from 10 to 18 years) collected at diagnosis. Protein profiles of 15 HL relapsed (R) patients were compared with 14 HL not relapsed (NR) patients treated with the same LH-2004 protocol. Two dimensional difference in gel electrophoresis (2D-DIGE) revealed significant differences (fold change > 1.5; Student's T-test p < 0.01) between R and NR patients in 10 proteins: α-1-antitrypsin chain a; apolipoprotein A-IV precursor; inter-α-trypsin inhibitor heavy chain; antithrombin-III; vitronectin; fibrinogen α, β and γ chains, complement C3, and ceruloplasmin. An up-regulation of fibrinogen α (spots 78, 196, 230, 234, 239) and β (spots 98, 291, 296, 300) chains together with a lower level of α-1-antitrypsin (spots 255, 264, 266, 272, 273) were found in R patients, and this difference was validated by immunoblotting. The functional role(s) of these proteins in the hemostasis and inflammation associated with pediatric/adolescent HL progression and relapse deserve further investigations.